Skip to evidence report

NEU.INH_VIP.develop_niche: Studies — page 10

How association tiers are defined — cell–trait and gene–trait

SCREATE tier definitions supplied by the atlas curator. This methods note explains the prepared classifications; it does not recompute or change any report scores or tiers.

Cell–trait tiers

Cell–trait links
Identify cell types whose regulatory activity is associated with a trait’s genetic signal.
Required for Specific or Relevant
The ICE-CREAM score derived from the mean metacell Z score must be ≥ 5.39, with BOTH nominal and adjusted ICE-CREAM P values ≤ 0.05.
Specific (Tier 1)
Also meets all cell-set enrichment analysis (CSEA) criteria in at least one tested comparison: nominal P ≤ 0.05 AND adjusted P ≤ 0.05 AND normalized enrichment score (NES) ≥ 1, all in that comparison. This indicates that trait-associated activity is concentrated in this cell type relative to the tested background.
Relevant (Tier 2)
Meets the ICE-CREAM requirements but not the additional CSEA criteria. The cell type may share trait-associated activity with other cell types.
Interpretation and report values
CSEA is cell-set enrichment analysis, analogous to gene-set enrichment analysis but using sets of cells along a ranked list of ICE-CREAM scores. The eligibility score derived from the mean metacell Z score is not the displayed mean IC score. Do not infer a tier from the displayed mean, its descriptive Significance column, or a single CSEA summary value. Reports preserve prepared tiers; Other means an available association outside Specific/Relevant, and unavailable is not zero or proof of biological irrelevance.
Meta traits and individual traits
Use the prepared tier for the exact meta trait or individual trait. A meta trait’s Best child CSEA FDR is the lowest available child FDR, not a combined or meta-trait significance test. Its displayed mean child NES is descriptive, not a new CSEA test. These summaries must not be used to reconstruct or override the meta-trait tier.

Gene–trait priorities (variant–tCRE–gene evidence)

Variant–tCRE–gene links
Candidate variants connect to genes through overlapping promoters or distal transcribed cis-regulatory elements (tCREs) linked to gene promoters by the Activity-by-Contact (ABC) model.
Required genetic support
The variant belongs to a purity-passing SuSiE credible set OR qualifies for Borzoi rescue. Borzoi rescue requires BOTH a variant-causality score ≥ 0.3 AND linkage disequilibrium with the lead variant of r² ≥ 0.2.
Required cellular support
The overlapping promoter has positive tCRE activity OR the distal element has a passing cell-specific ABC link to the gene, in a Specific or Relevant cell subtype (L1S) or fine-grained state (L2). BOTH genetic and cellular support are required for High or Medium priority.
High priority
Among records meeting both minimum requirements, High requires a genetic score ≥ 0.5 AND a Layer 1 correlation > 0.3 between tCRE activity and the trait’s cellular profile across cell subtypes.
Medium priority
Meets both minimum requirements but not one or both additional High thresholds. The genetic score is the higher of the SuSiE posterior inclusion probability (PIP) and the Borzoi variant-causality score.
Same-record evidence and aggregation
Each priority requires genetic and cellular evidence supporting the SAME variant–tCRE–gene record. Do not combine thresholds or evidence from different records to create a qualifying link. A gene receives the highest priority observed among its supporting records. A tCRE summary uses supporting records for that exact tCRE, not every trait of its linked genes. Separately displayed aggregate scores do not relax the same-record rule.
Limits of interpretation
A priority is candidate-association evidence, not proof of a causal variant, causal gene, causal cell type or treatment efficacy. Missing evidence is unavailable, not zero. MAGMA −log10(P), displayed credibility scores, cellular-context scores and G/C tier codes must not be substituted for these eligibility tests; use the provided records and their documented fields.

State · 122 full-atlas cells · all tissues.

Marker genes and cell annotation · Open this population in Cell Browser →

ICE-CREAM (IC) is −log10(P) from a permutation test. An IC score of 3 corresponds to an unadjusted P value of 0.001; 5.5 is the multiple-testing-corrected significance threshold across all metacells. The Significance categories are Significant for IC > 5.5, Nominal for 3 ≤ IC ≤ 5.5, and Nonsignificant for IC < 3. These reports display mean IC scores across full-atlas populations, not the UMAP sample. The categories apply to the displayed scores: a cell-group mean or an average across individual traits is descriptive and is not itself a newly tested P value or a new multiple-testing correction. All scores are retained. Enrichment is not proof of causality or treatment efficacy.

Rows 9,001–10,000 of 12,313; ranked by score descending. Equal values use name/identifier order.

Studies ranked for NEU.INH_VIP.develop_niche
#Trait / studyIndividual trait IDMean IC score
9001HAVCR2 levelsGCST904215151.37e-03
9002SLA2 levelsGCST904706481.37e-03
9003Other and/or unspecified nontoxic goitreFING000009581.37e-03
9004BACH1/EIF4G1 ratioGCST903134381.37e-03
9005PRKRA levelsGCST904703311.36e-03
9006Congenital malformations of the circulatory systemFING000003401.36e-03
9007Disorders of lipoprotein metabolism and other lipidaemiasFING000004421.36e-03
9008Phlebitis and thrombophlebitis (not including DVT)FING000011651.36e-03
9009ANGPT1/EGF ratioGCST903132641.35e-03
9010BleedingFING000002191.35e-03
9011Sphingomyelin_39:1_[M+H]1+ levelsGCST900603281.35e-03
9012Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T89ECGA0000891.35e-03
9013HLAE/IL15 ratioGCST903150611.35e-03
9014aparc-a2009s lh area S-orbital-med-olfactGCST900033591.35e-03
9015Cholesterol to total lipids in large VLDL percentage (UKB data field 23590)GCST902696871.34e-03
9016DTI TBSS MD Posterior corona radiata RGCST903845981.34e-03
90171-stearoyl-2-docosahexaenoyl-GPE (18:0/22:6) levelsGCST902000651.34e-03
9018PDGFB/SPINT2 ratioGCST903156291.34e-03
9019CASP1 levelsGCST904685431.34e-03
9020IDP dMRI TBSS ISOVF Posterior corona radiata LGCST900045041.34e-03
9021CELA3A/PLA2G1B ratioGCST903140141.34e-03
9022Free Cholesterol to Total Lipids in Small HDL percentageGCST904994311.33e-03
9023HPSE levelsGCST904694731.33e-03
9024Disorders of sclera, cornea, iris and ciliary bodyFING000004581.33e-03
9025Illnesses of father - None of the above (group 2) | Family historyUKBB000003461.33e-03
9026SCARA3 levelsGCST904278561.33e-03
9027MANF/PDGFB ratioGCST903153601.33e-03
9028C21orf58 levelsGCST906183801.33e-03
9029Phosphatidylcholine-O_33:3_[M+H]1+/Phosphatidylcholine-P_33:2_[M+H]1+/Phosphatidylethanolamine-O_36:3_[M+H]1+ levelsGCST900602611.33e-03
9030ITGB1/REG1A ratioGCST903152281.33e-03
9031Cardiovascular delta age (difference between ECG-predicted and chronological age)GCST902397491.32e-03
9032aparc-Desikan lh area pericalcarineGCST900030931.32e-03
9033IL19 levelsGCST904695681.32e-03
9034Triglycerides to total lipids in large VLDL percentage (UKB data field 23593)GCST902696901.31e-03
9035ICD10 O14: Pre-eclampsiaGCST904542331.31e-03
9036Saturated fatty acids levelsGCST905026711.31e-03
9037MYOM3 levelsGCST904699861.31e-03
9038Uric acid levelsGCST902786461.30e-03
9039hemoglobin (mean, inv-norm transformed)GCST904753761.30e-03
9040CRACR2A/LBR ratioGCST903142281.30e-03
9041Omega-6 fatty acid levelsGCST905025031.30e-03
9042Free cholesterol in very large HDLGCST905003831.30e-03
9043CRKL/MGLL ratioGCST903142701.30e-03
9044Systolic blood pressure, manual reading | Blood pressureUKBB000008101.30e-03
9045Total phospholipid levels in lipoprotein particlesGCST905001241.30e-03
9046C1QL2 levelsGCST904684871.30e-03
9047Calculus of lower urinary tract (PheCode 594.2)GCST904761461.29e-03
9048MINDY1 levelsGCST904699081.29e-03
9049Cholesteryl Esters to Total Lipids in Large VLDL percentageGCST904981651.29e-03
9050Triglycerides to Total Lipids in Large VLDL percentageGCST904982931.29e-03
9051CST3/CTSZ ratioGCST903142901.29e-03
9052TNFAIP2 levelsGCST904708961.29e-03
9053Psoriatic arthritisGCST902439561.29e-03
9054CXCL10 levelsGCST904689231.29e-03
9055Right-hemisphere visual network to right-hemisphere default mode network white-matter structural connectivityGCST903027801.28e-03
9056CALB1 levelsGCST904685261.28e-03
9057GRAP2/LACTB2 ratioGCST903149801.28e-03
9058Triglycerides in LDLGCST904984691.28e-03
9059Psoriasis and related disorder (PheCode 696)GCST904761861.28e-03
9060AmygNuclei rh volume Lateral-nucleusGCST900026581.28e-03
9061FCAR/LY96 ratioGCST903147881.28e-03
9062T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 41)GCST903206041.27e-03
9063Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T468ECGU0004681.27e-03
9064Prescriptions - biguanides|diabetesUKBB000006711.27e-03
9065Phospholipids to total lipids in chylomicrons and extremely large VLDL percentage (UKB data field 23579)GCST902696761.27e-03
9066Acute appendicitisFING000000171.27e-03
9067Phospholipids to total lipids in medium LDL percentage (UKB data field 23619)GCST902697161.27e-03
9068HEPH levelsGCST904694461.27e-03
9069Phospholipids in HDL (UKB data field 23414)GCST902695111.27e-03
9070Tibiofemoral angleGCST902702631.26e-03
9071RABGAP1L levelsGCST904704161.26e-03
9072Ulcerative colitisGCST904681521.26e-03
9073JAM2/RGMB ratioGCST903152371.26e-03
9074HYOU1/PTPRF ratioGCST903151021.26e-03
9075IDP T1 FAST ROIs R cerebellum crus IGCST900025711.26e-03
9076Creatinine levelsGCST900928151.26e-03
9077CLIP2/NT5C3A ratioGCST903141291.26e-03
9078aparc-pial lh area precentralGCST900031641.26e-03
9079Phosphatidylcholine levelsGCST904992481.26e-03
9080Cholesterol to total lipids ratio in very large HDLGCST900930051.26e-03
9081CASP3 levelsGCST904685451.26e-03
9082Pulmonary embolism and infarction, acute (PheCode 415.11)GCST904759461.25e-03
9083triglyceride (minimum, inv-norm transformed)GCST904764371.25e-03
9084MGLL/PDLIM7 ratioGCST903154381.25e-03
9085Barrett's esophagus (PheCode 530.13)GCST904760481.25e-03
9086NMNAT1 levelsGCST904700571.25e-03
9087Total lipid levels in lipoprotein particlesGCST905000851.25e-03
9088IGFBP6/PTGDS ratioGCST903151371.25e-03
9089AGRN/CRIM1 ratioGCST903132001.25e-03
9090S100A16 levelsGCST904705161.24e-03
9091AsthmaGCST0100421.24e-03
9092CD63/CLEC1B ratioGCST903138631.24e-03
9093CRELD2 levelsGCST904688591.24e-03
9094ADGRG2/ITGB1 ratioGCST903131851.23e-03
9095Average diameter for HDL particlesGCST904974461.23e-03
9096Platelet count during third trimester of pregnancyGCST903022261.23e-03
9097BCR/DECR1 ratioGCST903134891.23e-03
9098Prescriptions - metformin | biguanides,diabetesUKBB000006921.23e-03
9099Cervical cancerGCST900185971.23e-03
9100Triglyceride levels in large LDLGCST900928661.23e-03
9101GM2A levelsGCST904693651.23e-03
9102Diverticulosis and diverticulitis | digestiveUKBB000001911.23e-03
9103Endometrial cancerGCST0064641.22e-03
9104OGFR levelsGCST904701181.22e-03
9105Coronary atherosclerosisFING000003591.22e-03
9106Congenital malformations of heart and great arteriesFING000003361.22e-03
9107Triglycerides in medium HDL (UKB data field 23571)GCST902696681.22e-03
9108PTN levelsGCST904703741.21e-03
9109CLEC1B/DKK1 ratioGCST903140881.21e-03
9110CD58/ERBB3 ratioGCST903138481.21e-03
9111Paroxysmal tachycardiaFING000011511.21e-03
9112GRPEL1/MME ratioGCST903149921.21e-03
9113FUT8/VEGFC ratioGCST903148961.21e-03
9114BCL2L2 levelsGCST904220771.20e-03
9115KYAT1 levelsGCST904697211.20e-03
9116Bone marrow fat fraction of right proximal femurGCST906523931.20e-03
9117ITGB1/SELP ratioGCST903152301.20e-03
9118Linoleic acid to total fatty acids percentageGCST905020251.20e-03
9119Diverticulosis | digestiveUKBB000001901.20e-03
9120DTI autoptx L2 unc l tractGCST903851911.20e-03
9121ADA2/COMP ratioGCST903131661.20e-03
9122ICD10 N87: Dysplasia of cervix uteriGCST904542181.19e-03
9123Total triglycerides levelsGCST0036641.19e-03
9124Brainstem global volume MidbrainGCST900027671.19e-03
9125CST3/TFF3 ratioGCST903142991.19e-03
9126Intestinal infectious diseasesFING000006891.18e-03
9127CD55/ITGB1 ratioGCST903138461.18e-03
9128RWDD1 levelsGCST904705101.18e-03
9129DAPP1/PTPN6 ratioGCST903143971.18e-03
9130DNPH1/NSFL1C ratioGCST903145261.17e-03
9131Asthma | Chronic lower respiratory diseasesUKBB000000531.17e-03
9132Saturated fatty acids levelsGCST905021941.17e-03
9133CNST/PRKAR1A ratioGCST903141611.17e-03
9134ADH4/SORD ratioGCST903131961.17e-03
9135GSTA1/RBP5 ratioGCST903149951.17e-03
9136Operative procedures - Primary repair of inguinal hernia using insert of prosthetic material | Summary OperationsUKBB000005871.16e-03
9137wg lh intensity-contrast caudalmiddlefrontalGCST900037951.16e-03
9138HyperthyroidismGCST903193191.16e-03
9139CASP8/DDX58 ratioGCST903136511.16e-03
9140HEXIM1/IPCEF1 ratioGCST903150461.16e-03
9141Plasma 2-aminobutyrate levels in chronic kidney diseaseGCST902643391.16e-03
9142PDGFA/VEGFC ratioGCST903156221.16e-03
9143Varicose veins of lower extremities | Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classifiedUKBB000008941.15e-03
9144FKBPL levelsGCST904692461.15e-03
9145IRAK4/VASH1 ratioGCST903152011.15e-03
9146CD22/SEMA7A ratioGCST903137591.14e-03
9147IDP dMRI TBSS L1 Sagittal stratum LGCST900041061.14e-03
9148LTA levelsGCST904698131.14e-03
9149B4GAT1 levelsGCST904684131.14e-03
9150Cholesterol in Medium LDLGCST904987031.14e-03
9151High light scatter reticulocyte percentage of red cellsGCST900023861.14e-03
9152IL1R2/MEGF9 ratioGCST903151591.13e-03
9153Gamma-CEHC glucuronide levelsGCST901999411.13e-03
9154FCER2/TREML2 ratioGCST903147921.13e-03
9155Eosinophill count | Blood countUKBB000002061.13e-03
9156PTGDS levelsGCST904703681.13e-03
91571-palmitoyl-2-oleoyl-GPE (16:0/18:1) metabolite levelGCST906164031.13e-03
9158NIT2 levelsGCST904700511.13e-03
9159DTI TBSS FA Anterior corona radiata RGCST903844021.12e-03
9160Platelet count during first trimester of pregnancyGCST903022241.12e-03
9161MEGF9 levelsGCST904698841.12e-03
9162CANT1/NUDT5 ratioGCST903136191.12e-03
9163Alanine aminotransferase | Blood biochemistryUKBB000000181.11e-03
9164SpondylopathiesFING000013251.11e-03
9165FOLH1 levelsGCST904692581.11e-03
9166HSDL2 levelsGCST904694851.11e-03
9167Right-hemisphere limbic network to hippocampus white-matter structural connectivityGCST903028311.11e-03
9168IGFBP6/MFAP5 ratioGCST903151351.11e-03
9169MANF/TXNDC5 ratioGCST903153701.10e-03
9170DARS1 levelsGCST904689471.10e-03
9171GOPC levelsGCST904693771.10e-03
9172Polyunsaturated fatty acid levelsGCST905026181.10e-03
9173ENO2/PRSS27 ratioGCST903146661.10e-03
9174Atopic dermatitisGCST900271611.10e-03
9175HippSubfield lh volume Whole-hippocampal-bodyGCST900026871.10e-03
9176DAB2/ERBIN ratioGCST903143611.10e-03
9177LRIG1 levelsGCST904697941.09e-03
9178PPM1B levelsGCST904702961.09e-03
9179DKK1/LGALS8 ratioGCST903144721.09e-03
9180HS6ST1 levelsGCST904694791.09e-03
9181Sleep apnea | neurologicalUKBB000007741.09e-03
9182CCL7 levelsGCST904685851.08e-03
9183BCR levelsGCST904684361.08e-03
9184IL6ST levelsGCST904696031.08e-03
9185IDP T1 SIENAX white normalised volumeGCST900024321.08e-03
9186Nontoxic uninodular goiter (PheCode 241.1)GCST904756401.08e-03
9187Phospholipids to Total Lipids in Medium HDL percentageGCST904986511.08e-03
9188LGALS4 levelsGCST904697621.08e-03
9189PDLIM7 levelsGCST904701981.08e-03
9190LBR/PSRC1 ratioGCST903153001.08e-03
9191Psoriasis (PheCode 696.4)GCST904761871.08e-03
9192DTI autoptx L1 cst l tractGCST903851471.07e-03
9193Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T481ECGU0004811.07e-03
9194TriglyceridesGCST0022161.07e-03
9195IRAK1 levelsGCST904696271.07e-03
9196Ischaemic heart disease, wide definitionFING000007031.07e-03
9197PDGFB/UXS1 ratioGCST903156341.07e-03
9198KDR levelsGCST904696721.07e-03
9199Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T104ECGA0001041.07e-03
9200SMAD3 levelsGCST904706771.06e-03
9201Polyunsaturated fatty acid levelsGCST905026071.06e-03
9202FUT8/SPARC ratioGCST903148931.06e-03
9203AGER levelsGCST900120541.06e-03
9204NCR3LG1 levelsGCST904700101.06e-03
9205BIN2 levelsGCST904684451.06e-03
9206ADAMTS15 levelsGCST904682231.06e-03
9207FABP3 levelsGCST904691751.06e-03
9208Asthma | respiratoryUKBB000000541.06e-03
9209IDP dMRI ProbtrackX MD atr rGCST900042221.06e-03
9210Lymphoid neoplasmsGCST906247431.06e-03
9211REST UKBBICA NET100 1212GCST903870661.06e-03
9212TOMM20 levelsGCST904709311.06e-03
9213MYL3 levelsGCST904699771.06e-03
9214BIN2/FYB1 ratioGCST903135051.05e-03
9215CD300LG/CLEC14A ratioGCST903138011.05e-03
9216IDI2 levelsGCST904695051.05e-03
9217CCL17/GRK5 ratioGCST903136871.05e-03
9218HemoglobinGCST900187371.05e-03
9219Triacylglycerol_46:5_[M+NH4]1+ levelsGCST900603561.04e-03
9220Primary biliary cholangitis (PBC)FING000012111.04e-03
9221HSPB6 levelsGCST904694901.04e-03
9222Saturated fatty acids to total fatty acids percentageGCST905027011.04e-03
9223Myocardial fractal dimension (slice 7)GCST900002931.04e-03
9224CCN3/FAP ratioGCST903137211.04e-03
9225Linoleic acid levelsGCST905020041.04e-03
9226STAB2 levelsGCST904707551.04e-03
9227Diabetes (weighted GWA)GCST902672791.04e-03
9228FGF21/LEP ratioGCST903148101.03e-03
9229T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 6)GCST903208251.03e-03
9230Bilirubin (E,Z or Z,E) levelsGCST902437501.03e-03
9231IGFBP6 levelsGCST904695311.03e-03
9232KIT levelsGCST904696921.02e-03
9233CNDP1/EGFR ratioGCST903141461.02e-03
9234PFKFB2/SRP14 ratioGCST903156501.02e-03
9235IL16 levelsGCST902415961.02e-03
9236Left-hemisphere dorsal attention network to right-hemisphere visual network white-matter structural connectivityGCST903026941.02e-03
9237PPP1R12A levelsGCST904703001.02e-03
9238TXNDC5 levelsGCST904709911.01e-03
9239Hippocampal subfield left CA3 volume (body)GCST902679401.01e-03
9240High density lipoprotein cholesterol levelsGCST902396511.01e-03
9241CDC26 levelsGCST904686631.01e-03
9242DTI TBSS MD Fornix cres+Stria terminalis RGCST903846101.01e-03
9243Nasal polyps (PheCode 471)GCST904760191.01e-03
9244ENG/NOTCH1 ratioGCST903146481.01e-03
9245Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T16ECGU0000161.01e-03
9246UXS1 levelsGCST904710231.00e-03
9247CCN1/DNAJB1 ratioGCST903137091.00e-03
9248SRC/STAT5B ratioGCST903158821.00e-03
9249TNFSF8 levelsGCST904709231.00e-03
9250DLL4 levelsGCST904690059.96e-04
9251GAPDH levelsGCST904693029.96e-04
9252F11 levelsGCST904691659.96e-04
9253FUT3 levelsGCST902412169.96e-04
9254Free cholesterol in large VLDLGCST904981859.95e-04
9255SCPEP1 levelsGCST904705539.94e-04
9256Urate levelsGCST0017919.94e-04
9257Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T107ECGA0001079.91e-04
9258Linoleic acid levelsGCST905022959.90e-04
9259Colitis, primary sclerosing, strict definitionFING000003139.88e-04
9260FHIT/PARK7 ratioGCST903148219.87e-04
9261Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T116ECGA0001169.85e-04
9262Chronic Kidney Disease, Stage IV (PheCode 585.34)GCST904761309.84e-04
9263EFNA4/TNFRSF9 ratioGCST903146069.83e-04
9264Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T17ECGU0000179.83e-04
9265Chronic iridocyclitisFING000002879.80e-04
9266T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 74)GCST903206379.79e-04
9267DNMBP/PTPN1 ratioGCST903145179.78e-04
9268IDP T1 FAST ROIs V cerebellum VIGCST900025679.77e-04
9269HPCAL1/PMVK ratioGCST903150769.77e-04
9270Psoriasis vulgaris (PheCode 696.41)GCST904761909.76e-04
9271EDAR levelsGCST904255569.75e-04
9272Varicose veins of lower extremity | circulatory systemUKBB000008959.74e-04
9273T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 57)GCST903206209.72e-04
9274LAT/SPARC ratioGCST903152889.72e-04
9275GFRA1/TNFRSF1A ratioGCST903149249.71e-04
9276NTRK2 levelsGCST904700979.70e-04
9277Left-hemisphere default mode network to right-hemisphere visual network white-matter structural connectivityGCST903027609.66e-04
9278Fatty acid(20:3)_[M-H]1- levelsGCST900601179.64e-04
9279Peripheral artery diseaseGCST900186709.63e-04
9280VPS37A levelsGCST904710469.62e-04
9281AsthmaGCST0068629.62e-04
9282Type 2 diabetesGCST900860729.61e-04
9283Parental longevity (father's age at death)GCST0067009.60e-04
9284PDIA4 levelsGCST904701959.58e-04
9285CD99/MMP3 ratioGCST903139289.58e-04
9286Malignant neoplasm of rectum, excluding all cancers (controls excluding all cancers)FING000007719.56e-04
9287Total lipids in IDLGCST904975949.55e-04
9288MAP2K6 levelsGCST904698529.52e-04
9289Gout (PheCode 274.1)GCST904757359.52e-04
9290HippSubfield lh volume subiculum-headGCST900026719.45e-04
9291SLMAP levelsGCST904706739.42e-04
9292DNAJC21 levelsGCST904690169.42e-04
9293ABL1/DNMBP ratioGCST903131499.41e-04
9294DTI TBSS FA Sagittal stratum LGCST903844119.41e-04
9295Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T120ECGU0001209.38e-04
9296CCL2/CCL7 ratioGCST903136969.38e-04
9297PM20D1 levelsGCST904702689.36e-04
9298FOLR3/KLK8 ratioGCST903148689.36e-04
9299ADAM23 levelsGCST902409229.35e-04
9300Irregular mensesFING000007019.33e-04
9301COL5A1 levelsGCST904688209.32e-04
9302SLITRK1 levelsGCST904706699.29e-04
9303Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T67ECGA0000679.29e-04
9304Linoleic acid levelsGCST905023069.28e-04
9305Primary biliary cholangitisGCST0031299.27e-04
9306PSME2 levelsGCST904703619.27e-04
9307SIGLEC1/SSC5D ratioGCST903158449.25e-04
9308GZMA/IL12A_IL12B ratioGCST903150099.25e-04
9309mean corpuscular volume (MCV, maximum, inv-norm transformed)GCST904754669.24e-04
93101-(1-enyl-palmitoyl)-GPC (p-16:0) levelsGCST901998999.24e-04
9311RFC4 levelsGCST904704609.22e-04
9312SCRN1 levelsGCST904705569.19e-04
9313IDP dMRI TBSS ICVF Cingulum hippocampus RGCST900043639.19e-04
9314CD79B/CKAP4 ratioGCST903138989.18e-04
9315Alanine aminotransferase levelsGCST902786179.17e-04
9316Autorefraction - 6mm strong meridian angle (left) | EyesightUKBB000000779.16e-04
9317CREG1 levelsGCST904688579.16e-04
9318Other obstetric traumaFING000010829.16e-04
9319SERPINH1 levelsGCST904706019.15e-04
9320MEP1B levelsGCST904698889.14e-04
9321Abnormal results of function study of liver (PheCode 573.7)GCST904760979.13e-04
9322LPCAT2/SERPINB8 ratioGCST903153289.13e-04
9323LGALS1 levelsGCST904697599.08e-04
9324CA4/PECAM1 ratioGCST903135869.05e-04
9325Left-hemisphere control network to right-hemisphere dorsal attention network white-matter structural connectivityGCST903027479.02e-04
9326Total fatty acid levelsGCST905022129.01e-04
9327CEP85 levelsGCST904687169.01e-04
9328Cancer code, self-reported: prostate cancer (UKB data field 20001_1044)GCST900419059.00e-04
9329LAT2/SDC4 ratioGCST903152788.96e-04
9330FCRL5/LY96 ratioGCST903148038.95e-04
9331EVI5 levelsGCST904691588.95e-04
9332Lung cancer in never smokersGCST902774348.94e-04
9333Saturated fatty acids levelsGCST905026758.93e-04
9334CD27/DLL1 ratioGCST903137718.92e-04
9335Idiopathic pulmonary fibrosisFING000006598.92e-04
9336GP1BA/SIAE ratioGCST903149598.91e-04
9337Anomalies of dental arch relationship, including avohilmoFING000000918.89e-04
9338Microalbumin urineGCST902786398.87e-04
9339eosinophil (absolute count, maximum, inv-norm transformed)GCST904752888.86e-04
9340CTSE levelsGCST904689118.85e-04
9341Acute renal failureFING000000308.85e-04
9342BA-exvivo rh area perirhinalGCST900032338.85e-04
9343CRELD2/ERP44 ratioGCST903142538.82e-04
9344MAP3K5/MAVS ratioGCST903153798.79e-04
9345IL34 levelsGCST904695938.77e-04
9346ITGB1 levelsGCST904696438.77e-04
9347Treatment or medication use - rosuvastatin (UKB data field 20003_1141192410)GCST900425398.75e-04
9348ANXA11 levelsGCST904683158.75e-04
9349DTI TBSS L1 Cingulum cingulate gyrus LGCST903844638.72e-04
9350EGFLAM levelsGCST904690848.71e-04
9351Asthma-related acute respiratory infectionsFING000001178.71e-04
9352PLPBP levelsGCST904702608.69e-04
9353IDP T1 SIENAX white unnormalised volumeGCST900024338.69e-04
9354Polyunsaturated fatty acids to total fatty acids percentageGCST904993028.68e-04
9355IGSF21 levelsGCST904695388.67e-04
9356CD27/NBL1 ratioGCST903137748.67e-04
9357Eosinophill count (UKB data field 30150)GCST904680688.66e-04
9358CCL4 levelsGCST0044338.65e-04
9359MZT1 levelsGCST904699888.63e-04
9360SIAE/SNAP29 ratioGCST903158438.61e-04
9361Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T23ECGU0000238.60e-04
9362PAXX levelsGCST904701618.59e-04
9363Phospholipids in large LDLGCST904980498.56e-04
9364End-diastolic bi-ventricular shape (principal component 8)GCST904484878.56e-04
9365PILRA/TNFRSF1A ratioGCST903156558.55e-04
9366Cholesterol in IDLGCST904975018.55e-04
9367Sphingomyelin (d18:1/22:2, d18:2/22:1, d16:1/24:2) levelsGCST902000138.53e-04
9368NRCAM/NTRK2 ratioGCST903155528.53e-04
9369T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 60)GCST903206238.53e-04
9370TNFRSF4 levelsGCST904709138.51e-04
93715alpha-pregnan-3beta,20alpha-diol monosulfate (2) levelsGCST901998548.51e-04
9372Concentration of small LDL particlesGCST904996608.51e-04
9373DCN levelsGCST904689568.50e-04
9374Allergic disease (asthma, hay fever or eczema)GCST0050388.49e-04
9375Varicose veins | circulatory systemUKBB000008938.49e-04
9376Sphingomyelin (d17:1/16:0, d18:1/15:0, d16:1/17:0) levelsGCST902000178.49e-04
9377wg lh intensity-contrast middletemporalGCST900038068.49e-04
9378Malignant neoplasm of bladder (PheCode 189.21)GCST904755998.48e-04
9379PROS1 levelsGCST904703378.48e-04
9380QSOX1 levelsGCST904704028.46e-04
9381Free cholesterol in IDLGCST904975648.45e-04
9382Coronary artery plaque burdenGCST905030758.45e-04
9383Alanine aminotransferase levelsGCST900259798.45e-04
9384Placental weight (paternal genotype, adjusted for sex)GCST902751998.44e-04
9385Other malignant neoplasms of skin (=non-melanoma skin cancer), excluding all cancers (controls excluding all cancers)FING000010678.43e-04
9386Plasma iron levelsGCST901005468.42e-04
9387potassium (maximum, inv-norm transformed)GCST904763048.42e-04
9388COL28A1 levelsGCST904688158.39e-04
9389CDON/SCARA5 ratioGCST903139958.39e-04
9390TXNL1 levelsGCST904709938.38e-04
9391WFIKKN2 levelsGCST904710778.38e-04
9392TIMM10 levelsGCST904708678.35e-04
9393X-12749 levelsGCST902437708.34e-04
9394Cholesterol to total lipids in small VLDL percentage (UKB data field 23600)GCST902696978.34e-04
9395CDH3/TNFRSF21 ratioGCST903139538.32e-04
9396RNF41 levelsGCST904704858.32e-04
9397Sphingomyelin_40:3_[M+H]1+ levelsGCST900603488.31e-04
9398Cholesteryl esters in medium LDL (UKB data field 23541)GCST902696388.30e-04
9399Other embolism and thrombosisFING000010438.29e-04
9400SLAMF1 levelsGCST902748358.28e-04
9401Omega-6 fatty acid levelsGCST905025198.28e-04
9402Autorefraction - 3mm strong meridian angle (right) | EyesightUKBB000000688.28e-04
9403TMED8 levelsGCST904708858.25e-04
9404ESAM/VSIR ratioGCST903147218.24e-04
9405MYOC levelsGCST904699838.22e-04
9406L3HYPDH levelsGCST904697248.19e-04
9407Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T113ECGA0001138.19e-04
9408Pregnenediol disulfate (C21H34O8S2) levelsGCST901998408.17e-04
9409CCL18 levelsGCST904685708.15e-04
9410FHIT/MAX ratioGCST903148188.15e-04
9411PMM2 levelsGCST904702708.14e-04
9412Cholesteryl Esters to Total Lipids in Small LDL percentageGCST904995958.13e-04
9413End-diastolic bi-ventricular shape (principal component 3)GCST904484828.13e-04
9414TREML2 levelsGCST904709628.13e-04
9415Cerebrospinal fluid sulfate* levelsGCST903180568.10e-04
9416CLEC4G/SEMA3F ratioGCST903141238.10e-04
9417Acute appendicitis, no complicationsFING000000188.09e-04
9418TOP2B levelsGCST904709348.08e-04
9419CD99/PIK3IP1 ratioGCST903139298.08e-04
9420Infections of the skin and subcutaneous tissueFING000006708.08e-04
9421SIAE levelsGCST904706298.06e-04
9422Secondary hypothyroidism (PheCode 244.1)GCST904756498.06e-04
9423Eye problems/disorders - Cataract | EyesightUKBB000002308.05e-04
9424PAM levelsGCST904701568.05e-04
9425CRACR2A levelsGCST904688538.04e-04
9426CTSO/IGF2R ratioGCST903143178.04e-04
9427CA3/HMBS ratioGCST903135848.02e-04
9428FCRL5/TNFRSF13B ratioGCST903148058.02e-04
9429Total Lipids in VLDLGCST905002348.02e-04
9430DKK4 levelsGCST904689998.02e-04
9431Ischemic strokeGCST900186448.02e-04
9432PPIF levelsGCST904702938.00e-04
9433Metabolic syndromeGCST904444897.97e-04
9434FCGR2A/FCGR2B ratioGCST903147937.97e-04
9435Illnesses of father - Lung cancer | Family historyUKBB000003447.96e-04
9436Other benign neoplasms of skinFING000009717.96e-04
9437RETN levelsGCST900120347.95e-04
9438Immature fraction of reticulocytesGCST0046287.94e-04
9439Illnesses of mother - None of the above (group 1) | Family historyUKBB000003497.92e-04
9440Degree of unsaturationGCST905022317.91e-04
9441Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T129ECGA0001297.89e-04
9442ThalamNuclei rh volume MDlGCST900027487.89e-04
9443Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T18ECGU0000187.86e-04
9444IDP dMRI ProbtrackX FA cgc rGCST900039307.84e-04
9445LSIL lesion of the cervix uteriFING000007327.83e-04
9446Total lipids in medium HDL (UKB data field 23566)GCST902696637.82e-04
9447SNCA levelsGCST904706947.82e-04
9448ThyrotoxicosisFING000013607.81e-04
9449Placental weight (paternal genotype, adjusted for sex and gestational age)GCST902751917.81e-04
9450PCYT2 levelsGCST904701787.81e-04
9451ICAM3/LY9 ratioGCST903151217.80e-04
9452APOB levelsGCST904971377.80e-04
9453BMP6 levelsGCST904684547.79e-04
9454Other demyelinating diseases of the central nervous systemFING000009957.79e-04
9455Lysophosphatidylcholine (26:0) [sn2] levelsGCST900241897.77e-04
9456CST5 levelsGCST904688957.76e-04
9457Red blood cell countGCST900187517.76e-04
9458Plasma X-24947 levels in chronic kidney diseaseGCST902668167.75e-04
9459AP3B1 levelsGCST904683257.74e-04
9460Disorders of vestibular function (Vertigo)FING000004647.73e-04
9461Waist-to-hip ratio adjusted for BMIGCST0122307.72e-04
9462Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T88ECGU0000887.72e-04
9463DAB2/ZBTB16 ratioGCST903143707.70e-04
9464IDP dMRI TBSS L3 Posterior limb of internal capsule RGCST900041897.70e-04
9465rfMRI amplitudes (ICA100 node 27)GCST900046157.69e-04
9466GALNT10/SEMA7A ratioGCST903149157.67e-04
9467Triacylglycerol_51:4_[M+NH4]1+ levelsGCST900604917.67e-04
9468TBCA levelsGCST904708127.65e-04
94693-methyl-2-oxobutyrate levelsGCST901996777.64e-04
9470CTSF/NAAA ratioGCST903143147.64e-04
9471Bone density Z-scoreGCST902786217.63e-04
9472PPY levelsGCST904703097.62e-04
9473CRTAP levelsGCST904688727.62e-04
9474Left ventricular end systole anterior wall thicknessGCST902785127.61e-04
9475TNFRSF14/TNFSF14 ratioGCST903159367.61e-04
9476Lysophosphatidylcholine (26:0) [sn1] levelsGCST900254277.61e-04
9477Sequelae of cerebrovascular diseaseFING000012947.58e-04
9478CC2D1A/WWP2 ratioGCST903136687.58e-04
9479Aortic aneurysm (PheCode 442.1)GCST904759937.57e-04
9480CD40LG/EREG ratioGCST903138207.56e-04
9481Primary sclerosing cholangitisGCST0040307.54e-04
9482AGER levelsGCST904682527.53e-04
9483Triglycerides to Total Lipids in Medium VLDL percentageGCST904990697.53e-04
9484Other hypertrophic and atrophic conditions (PheCode 701)GCST904761977.49e-04
9485Cholesteryl Esters to Total Lipids in Very Large VLDL percentageGCST905005697.49e-04
9486CD84/VASH1 ratioGCST903139207.49e-04
9487NUMB levelsGCST904701087.47e-04
9488CDHR1 levelsGCST904686787.46e-04
9489CTSF/CTSV ratioGCST903143137.46e-04
9490Thick vs thin eyebrowsGCST0060937.46e-04
9491FHIT levelsGCST904692387.45e-04
9492HMOX2/TDRKH ratioGCST903150677.45e-04
9493Red blood cell countGCST902786417.41e-04
9494triglyceride (mean, inv-norm transformed)GCST904764337.40e-04
9495DFFA levelsGCST904689877.40e-04
9496Free Cholesterol to Total Lipids in Medium HDL percentageGCST904985807.40e-04
9497Percentage of monosialylation of core-fucosylated monogalactosylated structures without bisecting GlcNAc (GP41)GCST906684857.40e-04
9498Phospholipids to Total Lipids in IDL percentageGCST904976427.38e-04
9499CST3/RARRES2 ratioGCST903142957.37e-04
9500LAT/PDGFA ratioGCST903152857.36e-04
9501Triglycerides to Total Lipids in Very Large HDL percentageGCST905005087.34e-04
9502total cholesterol (maximum, inv-norm transformed)GCST904764187.33e-04
9503NUDT5 levelsGCST904701077.33e-04
9504MYO9B levelsGCST904699827.32e-04
9505CCN2/TACC3 ratioGCST903137177.31e-04
9506Subpubic angleGCST904489087.29e-04
9507Gastroduodenal ulcerFING000005657.28e-04
9508Clonal hematopoiesis (DNMT3A mutation)GCST904353547.28e-04
9509BAX/MAX ratioGCST903134667.28e-04
9510REST UKBBICA NODEamps25 0014GCST903854977.27e-04
9511Percentage of M9 (GP18)GCST906684627.27e-04
9512Disorders of synovium and tendonFING000004627.26e-04
9513Triglycerides in medium LDLGCST904988707.26e-04
9514CA13/QDPR ratioGCST903135647.23e-04
9515Phospholipids in very small VLDLGCST905008407.23e-04
9516Docosahexaenoic acid to total fatty acids percentageGCST905022847.21e-04
9517KIFBP/TACC3 ratioGCST903152497.21e-04
9518VAMP5 levelsGCST904710247.19e-04
9519MEPE levelsGCST904698897.18e-04
9520Hypothyroidism, strict autoimmuneFING000006567.18e-04
9521Sphingomyelin_38:1_[M+H]1+ levelsGCST900603067.16e-04
9522Diseases of middle ear and mastoidFING000004277.16e-04
9523Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T64ECGA0000647.16e-04
9524Gout and other crystal arthrop (PheCode 274)GCST904757317.16e-04
9525DEFA1 or DEFA1B levelsGCST904689797.15e-04
9526RPN1 levelsGCST902409647.15e-04
9527TYRP1 levelsGCST904709987.14e-04
9528DUT levelsGCST904690547.13e-04
9529Total cholesterol minus HDL-C levelsGCST904991297.13e-04
9530Neoplasm of uncertain behavior (PheCode 199)GCST904756067.13e-04
9531ENO2/RWDD1 ratioGCST903146677.13e-04
9532PTS levelsGCST904703907.13e-04
9533Triglyceride levels in IDLGCST900928417.12e-04
9534SERPINA6 levelsGCST904705867.12e-04
9535Occlusion and stenosis of precerebral arteries (PheCode 433.1)GCST904759867.10e-04
9536NUDT5/SERPINB1 ratioGCST903155817.10e-04
9537CTSD levelsGCST904689107.09e-04
9538FSTL1 levelsGCST904692717.09e-04
9539DYNLT1 levelsGCST904690577.08e-04
9540Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T106ECGA0001067.08e-04
9541USO1 levelsGCST904710187.07e-04
9542ISLR2 levelsGCST904696297.06e-04
9543T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 6)GCST903205697.06e-04
9544Plasma X-25279 levels in chronic kidney diseaseGCST902668357.05e-04
9545Spinal stenosisFING000013227.04e-04
9546Phospholipids to total lipids in IDL percentage (UKB data field 23609)GCST902697067.03e-04
9547CDH3 levelsGCST904686747.03e-04
9548IDP dMRI TBSS OD Pontine crossing tractGCST900044037.03e-04
9549Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T90ECGU0000907.03e-04
9550CD300LG/DSG2 ratioGCST903138027.03e-04
9551Nephritis and nephropathy without mention of glomerulonephritis (PheCode 580.3)GCST904761157.01e-04
9552LGMN levelsGCST904697666.99e-04
9553Free Cholesterol to Total Lipids in Small HDL percentageGCST904994366.97e-04
9554CD48/FCRL6 ratioGCST903138406.97e-04
9555VSTM2L levelsGCST904710576.96e-04
9556GSTA3/KRT18 ratioGCST903149976.96e-04
9557Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T10ECGA0000106.96e-04
9558CSNK2A1 levelsGCST904688896.94e-04
9559High light scatter reticulocyte countGCST900023856.93e-04
9560Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T110ECGA0001106.93e-04
9561CBLIF levelsGCST904685526.89e-04
9562Triglycerides to Total Lipids in Small LDL percentageGCST904997406.89e-04
9563TNFSF13B levelsGCST904709206.89e-04
9564HAVCR2 levelsGCST904694326.88e-04
9565Sphingomyelin (d18:1/14:0) levels/Sphingomyelin (d16:1/16:0) levelsGCST900251156.87e-04
9566Total lipids in large HDLGCST904978186.87e-04
9567Polyunsaturated fatty acids to monounsaturated fatty acids ratioGCST905025706.86e-04
9568Saturated fatty acids levelsGCST905021866.86e-04
95691-linoleoyl-GPI (18:2) levelsGCST901998216.85e-04
9570XPNPEP2 levelsGCST904710846.84e-04
9571B4GALT1/SPON2 ratioGCST903134346.84e-04
9572CCL17/CD69 ratioGCST903136846.84e-04
9573HippSubfield rh volume subiculum-headGCST900026936.82e-04
9574Left ventricular end diastole inferolateral wall thicknessGCST902785166.81e-04
9575IDP dMRI TBSS MO Medial lemniscus RGCST900039606.80e-04
9576XIAP levelsGCST904710836.80e-04
9577Cholesterol to Total Lipids in Very Large VLDL percentageGCST905005396.77e-04
9578Hip width to body height ratioGCST902702606.75e-04
9579BST2/MME ratioGCST903135396.75e-04
9580Blood urea nitrogen levelsGCST902786236.74e-04
9581Triacylglycerol_51:2_[M+NH4]1+ levelsGCST900604976.73e-04
9582IDP dMRI TBSS FA Retrolenticular part of internal capsule LGCST900038986.73e-04
9583Kynurenine levelsGCST902434776.73e-04
9584CLEC14A/EPHB4 ratioGCST903140796.72e-04
9585LACTB2 levelsGCST904697266.69e-04
9586BLVRB/HBQ1 ratioGCST903135256.67e-04
9587RSPO1/RSPO3 ratioGCST903157906.67e-04
9588Placental weight (fetal genotype, adjusted for sex and gestational age)GCST902751896.65e-04
9589NTRK3/SCARF2 ratioGCST903155716.65e-04
9590MPIG6B/PDGFB ratioGCST903154826.62e-04
9591Retinal detachments and defects (PheCode 361)GCST904758456.60e-04
9592ZBTB17 levelsGCST904710966.60e-04
9593T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 109)GCST903209286.58e-04
9594Operative procedures - Closed reduction of fracture of bone and fixation using nail or screw | Summary OperationsUKBB000005756.58e-04
9595Histidine levelsGCST904974816.57e-04
9596KLK8/WFDC12 ratioGCST903152596.56e-04
9597CLEC1B/LGALS8 ratioGCST903140966.55e-04
9598Polyunsaturated fatty acid levelsGCST900929396.53e-04
9599CCL11/CCL7 ratioGCST903136736.53e-04
9600Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T118ECGA0001186.52e-04
9601Mean arterial pressureGCST900187436.52e-04
9602MAD1L1 levelsGCST904698366.52e-04
9603BCAN/NCAN ratioGCST903134816.51e-04
9604LTB4R levelsGCST904221646.51e-04
9605COL24A1 levelsGCST904688146.51e-04
9606FADD/PLIN3 ratioGCST903147726.50e-04
9607Ulcerative colitisGCST904753226.49e-04
9608GZMH/KLRD1 ratioGCST903150166.48e-04
9609Left-hemisphere dorsal attention network to putamen white-matter structural connectivityGCST903027036.48e-04
9610ANXA4/FADD ratioGCST903132916.46e-04
9611Varicose veins of lower extremity (PheCode 454.1)GCST904760136.44e-04
9612HPCAL1/NUDC ratioGCST903150746.41e-04
9613CCN3 levelsGCST904685896.41e-04
9614Blood cell traits latent factor 9 (white cell)GCST905592516.40e-04
9615Cholesterol, totalGCST0022216.39e-04
9616IL18 levelsGCST904284116.38e-04
9617APP/CCL28 ratioGCST903133176.37e-04
9618Primary biliary cholangitisGCST900614406.36e-04
9619CDSN levelsGCST904686886.35e-04
9620T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 91)GCST903206546.35e-04
9621Mean corpuscular hemoglobinGCST900023906.34e-04
9622CHAD levelsGCST904687376.34e-04
9623BAG6 levelsGCST904684186.33e-04
9624CST3/DEFA1_DEFA1B ratioGCST903142916.32e-04
9625Oral glucose tolerance test-1hGCST905664226.30e-04
9626NTF3 levelsGCST904700946.30e-04
9627PLXNA4/SKAP2 ratioGCST903156856.30e-04
9628Free Cholesterol to Total Lipids in Chylomicrons and Extremely Large VLDL percentageGCST905009926.30e-04
9629BCR/GOPC ratioGCST903134916.30e-04
9630GADD45GIP1 levelsGCST904692936.29e-04
9631Spleen volumeGCST900166676.26e-04
9632Total lipids in medium HDLGCST904986046.26e-04
9633SPRR3 levelsGCST904707376.26e-04
9634Total protein levelsGCST900259956.25e-04
9635Total fatty acid levelsGCST905000616.24e-04
9636IDP dMRI TBSS L2 Retrolenticular part of internal capsule LGCST900041446.23e-04
9637ANXA1 levelsGCST902402966.23e-04
9638Cholesteryl Esters in HDLGCST904973576.17e-04
9639Triacylglycerol_48:3_[M+NH4]1+ levelsGCST900604186.17e-04
9640ADH4/KRT18 ratioGCST903131926.16e-04
9641SDC4/SELP ratioGCST903158176.15e-04
9642IL6ST/LIFR ratioGCST903151666.14e-04
9643Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T102ECGA0001026.13e-04
9644FOLR3 levelsGCST904692616.13e-04
9645Myocardial infarctionGCST900186576.13e-04
9646ERBB2/PTPRF ratioGCST903146886.12e-04
9647Saturated fatty acids to total fatty acids percentageGCST905022076.12e-04
9648Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T85ECGU0000856.12e-04
9649AXL levelsGCST904684066.10e-04
9650Total Cholesteryl ester levelsGCST900251886.10e-04
9651PSAP levelsGCST904265866.10e-04
9652IL32 levelsGCST904695916.08e-04
9653ADM levelsGCST900119966.08e-04
9654Alanine levelsGCST0036666.07e-04
9655Triacylglycerol_46:4_[M+NH4]1+ levelsGCST900603626.07e-04
9656CLEC1B/EGF ratioGCST903140896.07e-04
9657IL18BP levelsGCST904695646.06e-04
9658Rheumatoid arthritis (PheCode 714.1)GCST904762306.06e-04
9659Nonalcoholic steatohepatitisFING000008796.06e-04
9660CRACR2A/IRAG2 ratioGCST903142276.05e-04
9661KRT18 levelsGCST904697166.05e-04
9662Recent feelings of tiredness or low energy | DepressionUKBB000007406.04e-04
9663Lymphocyte countGCST0046276.04e-04
9664Bone density T-scoreGCST902786206.04e-04
9665Total lipids in very small VLDLGCST905008136.03e-04
9666Saturated fatty acids to total fatty acids percentageGCST904999666.02e-04
9667HLA-A levelsGCST904694576.01e-04
9668AmygNuclei lh volume Whole-amygdalaGCST900026576.01e-04
9669DCBLD2/PLA2G15 ratioGCST903144286.01e-04
9670BLMH/PEAR1 ratioGCST903135196.00e-04
9671ERP29 levelsGCST904691496.00e-04
9672Lymphoid neoplasms (drug group 1 phenocluster)GCST906247406.00e-04
9673MRAP levelsGCST900899105.99e-04
9674CHMP1A/RHOC ratioGCST903140535.97e-04
9675RRAS levelsGCST904704995.96e-04
9676HippSubfield lh volume GC-ML-DG-bodyGCST900026815.96e-04
9677LRTM2 levelsGCST904698085.95e-04
9678TYRO3 levelsGCST904709975.94e-04
9679Malignant neoplasm, excluding all cancers (controls excluding all cancers)FING000007805.94e-04
9680CD300E/LILRA5 ratioGCST903137985.93e-04
9681Triacylglycerol_51:3_[M+NH4]1+ levelsGCST900604945.92e-04
9682Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T137ECGU0001375.92e-04
9683CALCOCO1/CASP3 ratioGCST903135965.92e-04
9684ARHGAP45 levelsGCST904683555.91e-04
9685DTI autoptx MD unc l tractGCST903852455.90e-04
9686Triglyceride levels in LDLGCST900928905.89e-04
9687BPIFA2 levelsGCST904684615.88e-04
9688CST3/IL18BP ratioGCST903142945.88e-04
9689EDAR/ERBIN ratioGCST903145755.87e-04
9690OsteoarthritisGCST904681445.86e-04
96913-amino-2-piperidone levelsGCST902001885.84e-04
9692ITPA levelsGCST904696545.83e-04
9693Triacylglycerol_53:4_[M+NH4]1+ levelsGCST900605245.83e-04
9694N-acetylphenylalanine levelsGCST902006775.83e-04
9695ADGRG2/NRCAM ratioGCST903131865.82e-04
9696Respiratory disease (confirmatory factor analysis Factor 11)GCST903093455.81e-04
9697TNFRSF13B/TNFSF13B ratioGCST903159335.81e-04
9698Total fatty acid levelsGCST900929875.77e-04
9699Dihexosylceramide (d18:1/22:0) levelsGCST900253485.76e-04
9700Cholesterol in Small LDLGCST904995595.76e-04
9701DTI autoptx FA unc l tractGCST903851375.75e-04
9702X-21286 levelsGCST902005625.75e-04
9703SRPK2 levelsGCST904707435.74e-04
9704DCTN1/FXN ratioGCST903144305.73e-04
9705OMD/SOST ratioGCST903155855.72e-04
9706AXL/MCAM ratioGCST903134215.72e-04
9707Nonalcoholic fatty liver diseaseFING000008785.71e-04
9708DAG1/SCARF1 ratioGCST903143815.71e-04
9709Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T94ECGU0000945.67e-04
9710MMP12 levelsGCST904699165.66e-04
9711Triacylglycerol_52:6_[M+NH4]1+ levelsGCST900605045.66e-04
9712CST6/FABP9 ratioGCST903143015.65e-04
9713RGS10 levelsGCST904704655.65e-04
9714Triglycerides to Total Lipids in Medium LDL percentageGCST904988855.64e-04
9715Polyunsaturated fatty acid levelsGCST905021345.64e-04
9716Right subiculum volume (body)GCST902679805.64e-04
9717F2R/TMSB10 ratioGCST903147385.64e-04
9718HARS1 levelsGCST904694305.62e-04
9719AMBN levelsGCST904682875.62e-04
9720IDP dMRI ProbtrackX FA ifo rGCST900039385.62e-04
9721Peripheral vascular diseaseGCST904759965.60e-04
9722Radial peak diastolic strain rateGCST900190145.60e-04
9723ICAM2 levelsGCST904694995.60e-04
9724Other hypothyroidism | Disorders of thyroid glandUKBB000006115.58e-04
9725LAIR1 levelsGCST904697285.58e-04
9726eosinophil (fraction, minimum, inv-norm transformed)GCST904753035.55e-04
9727LAMP3/PRSS8 ratioGCST903152755.54e-04
9728ANGPT1/APP ratioGCST903132605.54e-04
9729Lung volumeGCST900166685.52e-04
9730GRP levelsGCST904694065.52e-04
9731Triacylglycerol_50:5_[M+NH4]1+ levelsGCST900604635.50e-04
9732IL1RL2 levelsGCST904695755.49e-04
9733SUSD1/THPO ratioGCST903158995.49e-04
9734Hypothyroidism | endocrine/metabolicUKBB000003355.49e-04
9735Triglycerides to total lipids in very large VLDL percentage (UKB data field 23588)GCST902696855.48e-04
9736T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 87)GCST903209065.48e-04
9737ITGB5/SIAE ratioGCST903152345.46e-04
9738Cholesteryl esters to total lipids ratio in small HDLGCST900929475.46e-04
9739HyperlipidemiaGCST900909945.45e-04
9740SCGB3A1 levelsGCST904705425.45e-04
9741PLA2G4A/SNAP29 ratioGCST903156695.45e-04
9742FLT3/FLT3LG ratioGCST903148595.45e-04
9743RGMB levelsGCST904704645.44e-04
9744APOM levelsGCST904683425.44e-04
9745ART3/RGMA ratioGCST903133625.41e-04
9746Mean corpuscular haemoglobin (UKB data field 30050)GCST904680845.40e-04
9747Lymphoid neoplasms (somatic mutation group 2 phenocluster)GCST906247505.39e-04
9748CLEC14A/TNFRSF21 ratioGCST903140825.39e-04
9749HEXIM1/IKBKG ratioGCST903150455.37e-04
9750eosinophil (absolute count, mean, inv-norm transformed)GCST904752915.37e-04
9751Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T489ECGU0004895.35e-04
9752RETN/RNASET2 ratioGCST903157685.35e-04
9753STMN3 levelsGCST902428945.35e-04
9754Alzheimer's disease (MTAG)GCST904490555.35e-04
9755CD69/EDAR ratioGCST903138755.34e-04
9756Other diseases of the digestive systemFING000010105.34e-04
9757GIPC3 levelsGCST904693485.33e-04
9758Waist-hip indexGCST0122285.32e-04
9759Polyunsaturated fatty acids to total fatty acids percentageGCST905026455.31e-04
9760ICAM4 levelsGCST904695015.31e-04
9761IDP dMRI ProbtrackX ICVF cgh rGCST900043825.31e-04
9762LTA/LTBR ratioGCST903153365.30e-04
9763IL2RA/NCR1 ratioGCST903151615.30e-04
9764Polyunsaturated fatty acids to total fatty acids percentageGCST905026495.29e-04
9765mean corpuscular hemoglobin (MCH, mean, inv-norm transformed)GCST904754465.29e-04
9766Polyunsaturated fatty acids to saturated fatty acids ratioGCST905025975.28e-04
9767Plasma 3-hydroxybutyroylglycine** levels in chronic kidney diseaseGCST902644885.28e-04
9768FBP1/GSTA1 ratioGCST903147865.28e-04
9769Volume of right accessory basal nucleusGCST904750095.27e-04
9770Glomerular filtration rate in non diabetics (creatinine)GCST0034015.27e-04
9771Alzheimer's disease (MTAG)GCST904490625.27e-04
9772GPLD1 levelsGCST900868905.25e-04
9773TNFSF12 levelsGCST902748465.20e-04
9774Aspartate aminotransferase (AST, mean, inv-norm transformed)GCST904751215.17e-04
9775Waist-to-hip ratio adjusted for BMIGCST900259965.17e-04
9776T1 FreeSurfer DK lh lateraloccipital areaGCST903855985.17e-04
9777ADH4/RBP5 ratioGCST903131945.12e-04
9778INPP1/NT5C3A ratioGCST903151775.12e-04
9779HyperthyroidismGCST904681365.11e-04
9780ANG levelsGCST904683075.11e-04
9781PECAM1 levelsGCST904702065.11e-04
9782BAIAP2 levelsGCST904684195.11e-04
9783Certain disorders involving the immune mechanismFING000002645.09e-04
9784SERPINA4 levelsGCST904705845.09e-04
9785Right-hemisphere somatomotor network to pallidum white-matter structural connectivityGCST903027975.08e-04
9786Lipoma of skin and subcutaneous tissue (PheCode 214.1)GCST904756195.08e-04
9787Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T494ECGU0004945.07e-04
9788IDP T1 FIRST left hippocampus volumeGCST900024445.06e-04
9789T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 47)GCST903206105.06e-04
9790MANF/SDC4 ratioGCST903153675.06e-04
9791CD276 levelsGCST904686145.05e-04
9792ANGPT1/DKK1 ratioGCST903132635.04e-04
9793NBL1/TGFBR2 ratioGCST903155155.04e-04
9794Lung adenocarcinomaGCST0047445.02e-04
9795Hyperglyceridemia (PheCode 272.12)GCST904757245.02e-04
9796Umbilical hernia (PheCode 550.4)GCST904760625.01e-04
9797INPPL1 levelsGCST904696195.01e-04
9798FHIT/PRTFDC1 ratioGCST903148235.00e-04
9799C1QTNF5 levelsGCST904684894.98e-04
9800DGKA levelsGCST904689894.97e-04
9801Hypothyroidism NOS | endocrine/metabolicUKBB000003364.97e-04
9802GP6/SEMA4D ratioGCST903149714.96e-04
9803FLT4 levelsGCST904692524.96e-04
9804eGFR in diabetes mellitus (loose) kidney healthy controls (full adjustment)GCST906247934.95e-04
9805NFATC1/SPRY2 ratioGCST903155394.95e-04
9806F9/PROC ratioGCST903147484.95e-04
9807CD70 levelsGCST904686454.95e-04
9808Linoleic acid levelsGCST905023114.94e-04
9809Hernia abdominopelvic cavityGCST900860874.93e-04
9810Bone marrow fat fraction of left proximal femurGCST906523924.93e-04
9811Triacylglycerol_56:5_[M+NH4]1+ levelsGCST900605544.92e-04
9812Omega-6 fatty acids to total fatty acids percentageGCST904992104.91e-04
9813THBS4 levelsGCST904708554.90e-04
9814SELP/VSIR ratioGCST903158224.89e-04
98155alpha-androstan-3alpha,17beta-diol monosulfate (1) levelsGCST901998584.89e-04
9816PLAU levelsGCST904702524.88e-04
9817TPP1 levelsGCST904709464.87e-04
9818T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 46)GCST903206094.87e-04
9819EczemaGCST904681264.87e-04
9820Alanine transaminase (ALT, minimum, inv-norm transformed)GCST904751154.87e-04
9821B4GALT1/SMOC2 ratioGCST903134334.87e-04
9822TNFRSF11A levelsGCST904709024.86e-04
9823CPXM1/HBEGF ratioGCST903142194.85e-04
9824Epstein-Barr virus EA-D antibody levelsGCST900068984.84e-04
9825LAMP1 levelsGCST904697334.81e-04
9826Phospholipids in IDLGCST904976284.81e-04
9827DTI TBSS MD Cingulum cingulate gyrus RGCST903846064.79e-04
9828Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T60ECGA0000604.79e-04
9829PAK4 levelsGCST904701504.79e-04
9830CRKL/DBNL ratioGCST903142634.75e-04
9831Free thyroxine levels within normal range in pregnancyGCST904351964.75e-04
9832triglyceride (maximum, inv-norm transformed)GCST904764294.75e-04
9833ATP5IF1/F2R ratioGCST903133844.75e-04
9834Tyrosine levelsGCST902434254.75e-04
9835Monounsaturated fatty acids to total fatty acids percentageGCST905020494.74e-04
9836Sphingomyelin_34:2_[M+H]1+ levelsGCST900602354.73e-04
9837Triglycerides to Total Lipids in Very Large HDL percentageGCST905005064.73e-04
9838Psoriasis vulgarisFING000012244.72e-04
9839DLK1 levelsGCST904690034.70e-04
9840CXCL11 levelsGCST904689244.70e-04
9841Diastolic blood pressureGCST900259814.69e-04
9842ITGB1BP2/TIA1 ratioGCST903152224.69e-04
9843EDAR/IPCEF1 ratioGCST903145784.68e-04
9844Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T107ECGU0001074.67e-04
9845CTSZ/NAAA ratioGCST903143204.67e-04
9846Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T118ECGU0001184.65e-04
9847ABL1 levelsGCST904681904.63e-04
9848Cholesteryl Esters to Total Lipids in IDL percentageGCST904975494.63e-04
9849EPCAM/GPA33 ratioGCST903146744.62e-04
9850Total lipids in large VLDLGCST904982164.59e-04
9851Asthma (childhood onset)GCST0078004.59e-04
9852DAG1/DBNL ratioGCST903143724.58e-04
9853SYTL4 levelsGCST904707954.58e-04
9854IDP dMRI TBSS L2 Cingulum hippocampus LGCST900041604.58e-04
9855BST2/CXADR ratioGCST903135384.56e-04
9856IGF2R/LGMN ratioGCST903151314.56e-04
9857GIT1 levelsGCST904693514.55e-04
9858CD20 on IgD- CD27- B cellGCST900017544.55e-04
9859lymphocyte (absolute count, mean, inv-norm transformed)GCST904754264.55e-04
9860Nonspecific elevation of levels of transaminase or lactic acid dehydrogenase [LDH] (PheCode 573.6)GCST904760944.55e-04
9861CCN4 levelsGCST904685904.55e-04
9862Phosphatidylcholine_34:2_[M+H]1+/Phosphatidylethanolamine_37:2_[M+H]1+/Phosphatidate_39:3_[M+NH4]1+ levelsGCST900603034.55e-04
9863SCAMP3 levelsGCST904705324.54e-04
9864Alkenylphosphatidylethanolamine (P-20:0/18:2) levelsGCST900250564.53e-04
9865Subclinical hyperthyroidism in pregnancyGCST904351994.52e-04
9866CA5A/KRT18 ratioGCST903135924.52e-04
9867ICA1 levelsGCST904694974.52e-04
9868CD38/RELT ratioGCST903138094.51e-04
9869Phospholipids to total lipids in small LDL percentage (UKB data field 23624)GCST902697214.50e-04
9870PSMD9/UBAC1 ratioGCST903157354.50e-04
9871CD69/F2R ratioGCST903138774.50e-04
9872Total fatty acid levelsGCST905027264.49e-04
9873SCAMP3/STX4 ratioGCST903158054.49e-04
9874T1 FreeSurfer aseg Right-choroid-plexusGCST903841704.47e-04
9875DNAJB14 levelsGCST904690114.47e-04
9876Treatment/medication code - salbutamol | MedicationsUKBB000008574.44e-04
9877Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T111ECGA0001114.44e-04
9878PTPN6 levelsGCST904703774.43e-04
9879Polyunsaturated fatty acids to monounsaturated fatty acids ratioGCST905025674.43e-04
9880DTI autoptx MD fma tractGCST903852304.43e-04
9881Phospholipids to Total Lipids in Large VLDL percentageGCST904982524.43e-04
9882PRTN3 levelsGCST904703484.42e-04
9883PTPRF/PTPRS ratioGCST903157514.42e-04
9884Edema (PheCode 782.3)GCST904762724.41e-04
9885CCN2/ENO2 ratioGCST903137124.39e-04
9886CDKN2D/FOXO1 ratioGCST903139854.38e-04
9887Triacylglycerol_54:3_[M+NH4]1+ levelsGCST900605414.37e-04
9888Mean corpuscular hemoglobinGCST0046304.36e-04
9889Spinal stenosis of lumbar region (PheCode 720.1)GCST904762344.36e-04
9890Triacylglycerol_50:2_[M+NH4]1+ levelsGCST900604734.35e-04
9891RUNX3 levelsGCST902427064.35e-04
9892Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T25ECGU0000254.34e-04
9893Octadecanedioylcarnitine (C18-DC) levelsGCST901999924.34e-04
9894LAT2 levelsGCST904697394.33e-04
9895Concentration of LDL particlesGCST904984134.33e-04
9896Alanine transaminase (ALT, mean, inv-norm transformed)GCST904751124.32e-04
9897RP2 levelsGCST904704934.32e-04
9898CD200R1/CLEC4G ratioGCST903137484.31e-04
9899ADGRE2/B4GALT1 ratioGCST903131744.31e-04
9900TNFRSF9 levelsGCST904709164.31e-04
9901Platelet distribution widthGCST0046164.29e-04
9902APOA1 levelsGCST904971224.29e-04
9903HMOX1 levelsGCST904694654.29e-04
9904BANK1/FOXO1 ratioGCST903134564.29e-04
9905ANGPTL3 levelsGCST904683044.29e-04
9906BCAN/DPP6 ratioGCST903134784.29e-04
9907Volume of right cortical nucleusGCST904749194.28e-04
9908FIS1 levelsGCST904692404.28e-04
9909GOT1 levelsGCST904693794.26e-04
9910CSF1/IFNGR1 ratioGCST903142834.24e-04
9911CXADR levelsGCST904689224.24e-04
9912Omega-6 fatty acids to total fatty acids percentageGCST905025414.23e-04
9913NECTIN2/VSIR ratioGCST903155334.23e-04
9914TCN1 levelsGCST904708194.23e-04
9915COL1A1/OMD ratioGCST903141714.23e-04
9916MTDH levelsGCST904699544.22e-04
9917APBB1IP/NADK ratioGCST903132984.22e-04
9918CD163/MSR1 ratioGCST903137384.22e-04
9919FAP/THBS4 ratioGCST903147854.21e-04
9920EGLN1/LSP1 ratioGCST903146174.20e-04
9921TWF2 levelsGCST904709874.19e-04
9922HBEGF/LAT2 ratioGCST903150324.18e-04
9923GALNT3 levelsGCST904692974.17e-04
9924EDAR/TXNDC5 ratioGCST903145934.16e-04
9925Frozen shoulderGCST900005134.16e-04
9926FADD/NFATC1 ratioGCST903147714.15e-04
9927CCL19 levelsGCST904685714.15e-04
9928CD244/CD84 ratioGCST903137624.15e-04
9929WFIKKN1 levelsGCST904710764.14e-04
9930CD300LF levelsGCST904686224.13e-04
9931Triacylglycerol_52:3_[M+NH4]1+ levelsGCST900605094.13e-04
9932HippSubfield lh volume Whole-hippocampal-headGCST900026884.13e-04
9933mean corpuscular hemoglobin (MCH, maximum, inv-norm transformed)GCST904754424.12e-04
9934Omega-6 fatty acids to total fatty acids percentageGCST905021294.12e-04
9935Rheumatoid arthritisGCST0006794.12e-04
9936BCAM/LGALS4 ratioGCST903134734.12e-04
9937KIF22 levelsGCST904696824.11e-04
9938AXIN1/CLIP2 ratioGCST903134044.10e-04
9939T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 106)GCST903209254.10e-04
9940Idiopathic goutFING000006584.09e-04
9941Free Cholesterol to Total Lipids in Large VLDL percentageGCST904982044.08e-04
9942LYPD3 levelsGCST904698284.07e-04
9943Omega-3 fatty acids to total fatty acids percentageGCST905020814.07e-04
9944GORASP2 levelsGCST904693784.07e-04
9945COL6A3/SMOC2 ratioGCST903141784.06e-04
9946lymphocyte (absolute count, minimum, inv-norm transformed)GCST904754294.06e-04
9947SCGN levelsGCST904705444.06e-04
9948Operative procedures - Haemorrhoidectomy | Summary OperationsUKBB000005804.05e-04
9949FCRL2 levelsGCST904692064.04e-04
9950SLPI levelsGCST904260304.04e-04
9951CST6/GAL ratioGCST903143024.03e-04
9952STIP1/TMSB10 ratioGCST903158904.03e-04
9953DNAJA2 levelsGCST904690094.03e-04
9954Triacylglycerol_56:4_[M+NH4]1+ levelsGCST900605564.03e-04
9955CD74 levelsGCST904686474.02e-04
9956JAM3 levelsGCST904696604.02e-04
9957PPP1R12A/VEGFC ratioGCST903157154.02e-04
9958ITGAM levelsGCST904696384.02e-04
9959INSL5 levelsGCST904696224.02e-04
9960DCBLD2 levelsGCST904689524.02e-04
9961CRKL/FIS1 ratioGCST903142664.01e-04
9962Cholesterol to Total Lipids in Medium VLDL percentageGCST904989194.00e-04
9963Other diseases of liverFING000010044.00e-04
9964Eosinophil percentage of white cellsGCST0046004.00e-04
9965AXIN1/HEXIM1 ratioGCST903134084.00e-04
9966NDUFB7 levelsGCST904700153.99e-04
9967Telomere length (principal component 2)GCST904351453.98e-04
9968CELA3A/CTRB1 ratioGCST903140113.97e-04
9969SOST levelsGCST904707113.96e-04
9970Type 1 diabetes with neurological manifestations (PheCode 250.14)GCST904756643.96e-04
9971DPY30 levelsGCST904690373.95e-04
9972Blood cell traits latent factor 3 (white cell)GCST905592453.95e-04
99731-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1) levelsGCST902000703.95e-04
9974Cholesterol to Total Lipids in Large VLDL percentageGCST904981253.94e-04
9975FYB1/PDGFB ratioGCST903149123.94e-04
9976Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T103ECGA0001033.94e-04
9977LTBR levelsGCST904698163.94e-04
997821-hydroxypregnenolone disulfate levelsGCST901998493.94e-04
9979Total free cholesterol levelsGCST905000633.93e-04
9980Concentration of small HDL particlesGCST904994613.93e-04
9981DTI autoptx L2 ifo r tractGCST903851793.93e-04
9982Acute laryngitis and tracheitisFING000000233.93e-04
9983ICAM5 levelsGCST904695023.91e-04
9984T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 66)GCST903206293.91e-04
9985CCL5/LAMA4 ratioGCST903137033.90e-04
9986ERP44 levelsGCST904691503.90e-04
9987Cholesterol in small HDL (UKB data field 23575)GCST902696723.90e-04
9988Monounsaturated fatty acids to total fatty acids percentageGCST905023853.89e-04
9989OGA levelsGCST904701173.89e-04
9990Polyunsaturated fatty acids to monounsaturated fatty acids ratioGCST905021533.88e-04
9991Non-albumin protein levelsUKBB000005033.88e-04
9992Concentration of small HDL particles (UKB data field 23572)GCST902696693.88e-04
9993IDP T1 FIRST right pallidum volumeGCST900024433.88e-04
9994TMSB10/TXNRD1 ratioGCST903159253.88e-04
9995SH3GLB2 levelsGCST904706213.87e-04
9996Neutrophil percentage of granulocytesGCST0046233.86e-04
9997ITGA5 levelsGCST904696353.84e-04
9998WWP2 levelsGCST904710803.84e-04
9999SnoringGCST0097633.84e-04
10000CNTN2 levelsGCST904688043.81e-04